Anavex Life Sciences (US:AVXL) Globenewswire·2025-07-31 11:30Core Insights - Anavex Life Sciences Corp. announced significant findings regarding its drug blarcamesine for early Alzheimer's disease, demonstrating up to 84.6 weeks (19.5 months) of 'time saved' through early treatment initiation [3][4][5] Group 1: Clinical Trial Results - The ATTENTION-AD Phase IIb/III trial showed that patients treated with blarcamesine continued to accrue cognitive and functional benefits over a period of up to 192 weeks [3] - In the intent-to-treat population, significant differences were observed in cognitive function (ADAS-Cog13) and daily living activities (ADCS-ADL) between early-start and late-start treatment groups at Week 192 [3] - The GWAS-identified population ABCLEAR24 showed even greater improvements in cognition (ADAS-Cog13: LS mean difference −5.43, P = 0.0035) and function (ADCS-ADL: LS mean difference +9.50, P < 0.0001) [3] Group 2: Mechanism of Action - Blarcamesine is confirmed to restore impaired autophagy by activating SIGMAR1, acting upstream of amyloid and tau pathologies [5][6] - The drug's mechanism was established through both in vitro and in vivo studies, demonstrating enhanced autophagic flux and increased proteostasis capacity [6][7] Group 3: Safety Profile - Blarcamesine exhibited a favorable safety profile with no treatment-related deaths reported during the trials [4][5] - Common treatment-emergent adverse events included transient dizziness, mostly mild to moderate in severity [8] Group 4: Future Implications - The findings suggest that earlier initiation of treatment with blarcamesine may significantly impact disease progression and provide sustained benefits for patients with early Alzheimer's disease [5][9] - The company emphasizes the importance of a long-term therapeutic strategy for chronic diseases like Alzheimer's, with blarcamesine's convenient once-daily oral dosing potentially enhancing patient adherence [9]